Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. ProMIS Neurosciences, Inc.
  6. News
  7. Summary
    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ProMIS Neurosciences : Completes US$7M Financing with Distinguished Group of Boston Based Investors

03/23/2021 | 09:38am EDT

TORONTO - ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce today the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures (the 'Debentures').

The investors include Mike Gordon of Fenway Sports Group, the Kraft Group, Henry McCance, co-founder of the Cure Alzheimer's Fund, and Jeremy Sclar of WS Development Group. 'After conducting diligence with a number of experts in the field, we are impressed with the tremendous potential of ProMIS Neurosciences and its unique platform of drug candidates to have a profound impact in the fight against Alzheimer's and other neurodegenerative diseases. Our group is pleased to provide funding for the next phase of the company's exciting future', stated Mike Gordon of Fenway Sports Group.

'We are honored to have the support of such a distinguished group of investors, all of whom are accomplished leaders in the business and life sciences arenas' said Gene Williams, ProMIS Executive Chairman.

Debenture Terms

The Debentures are convertible into ProMIS common shares at the option of the holder at a conversion price of US$0.10 per share and accrue interest at 1% per annum, which is payable annually. At the company's election, accrued interest may be paid in cash or common shares (such number of shares determined by dividing the interest due by the 5-day volume-weighted average trading price or 'VWAP' of the common shares).

The Debenture mature on March 22, 2026. Prior to the maturity date, the Company may force conversion of the Debentures at the conversion price upon raising US$50M in equity and/or debt cumulatively. On the maturity date, the Company may redeem the outstanding principal amount of the Debentures in either cash or common shares (at the then 5-day VWAP less a 10% discount) or a combination thereof at its election. Amounts redeemed in common shares on the Maturity Date will be subject to TSX acceptance.

The investors were granted a right to participate, on a pro rata basis, in subsequent company offerings of equity securities for cash consideration pursuant to a public offering or a private placement.

The Debentures and any common shares issued on conversion are subject to a four-month hold period that expires on July 22, 2021. Net proceeds will be used for working capital and general corporate purposes.

ProMIS plans to accelerate progress toward a number of top priorities, including: Advancing the PMN310 monoclonal antibody, our potential 'best in class' next generation Alzheimer's treatment, into clinical testing; Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data; Expanding our portfolio of products and intellectual property into new target areas, using our proprietary discovery platform; Advancing our partnered diagnostic programs; Achieving NASDAQ listing; Expanding our Board of Directors and Expanding our management team, capitalizing on the talent pool in Boston, to support a growing and ambitious scope of activity.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer's, ALS and Parkinson's disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Contact:

Nicholas Rigopulos

Tel: 617 901-0785

This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about PROMIS NEUROSCIENCES, INC.
08/02PROMIS NEUROSCIENCES : Presentations at 2021 Alzheimer's Association Internation..
PU
07/22PROMIS NEUROSCIENCES : to Present at 2021 Alzheimer's Association International ..
AQ
07/08PROMIS NEUROSCIENCES : Files Final Base Shelf Prospectus
MT
07/08ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus
GL
07/02PROMIS NEUROSCIENCES : Announces Results of Annual Meeting of Shareholders
PU
06/09PROMIS NEUROSCIENCES : congratulates Biogen on FDA accelerated approval of aduca..
AQ
06/08PROMIS NEUROSCIENCES : congratulates Biogen on FDA accelerated approval of aduca..
PU
06/07PROMIS NEUROSCIENCES : up 30% on FDA Approval of Biogen's Aducanumab
MT
06/03PROMIS NEUROSCIENCES : Files preliminary short form base shelf prospectus
PU
05/27ProMIS Neurosciences, Inc. Appoints Dr. David Wishart as Chief Physics Office..
CI
More news
Financials
Sales 2020 0,00 M 0,00 M 0,00 M
Net income 2020 -5,66 M -4,51 M -4,51 M
Net cash 2020 1,07 M 0,85 M 0,85 M
P/E ratio 2020 -3,96x
Yield 2020 -
Capitalization 59,7 M 47,5 M 47,5 M
EV / Sales 2019 37 534x
EV / Sales 2020 15 614x
Nbr of Employees -
Free-Float 81,2%
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Elliot Goldstein President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial Officer
Eugene Williams Executive Chairman
Neil R. Cashman Director & Chief Scientific Officer
William W. Wyman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PROMIS NEUROSCIENCES, INC.95.00%48
GILEAD SCIENCES, INC.17.22%85 723
BIONTECH SE317.33%82 168
WUXI APPTEC CO., LTD.41.52%69 241
REGENERON PHARMACEUTICALS18.94%59 765
VERTEX PHARMACEUTICALS-16.09%51 450